If biotech’s historic bull run is losing steam, as some observers believe, this week is one hell of a final stampede.
Mirati Therapeutics plans to raise more than $200 million this week in a public offering, funding that it plans to use to advance its lead cancer drug candidate, sitravatinib, into late-stage testing, and to continue developing its other targeted oncology programs.... Read more »
Southeast Michigan is now home to another unicorn startup.
Detroit-based e-commerce company StockX announced Wednesday that it has raised $110 million in a Series C funding round, increasing the company’s total value to more than $1 billion. The investment was led... Read more »
Youth. Charm. Fearlessness. Ruthless focus. These can be positive attributes in an entrepreneur, but in a more rational world, technology investors wouldn’t overvalue them. Risk capital would be allocated based mostly on evidence, data, progress towards milestones—in short, on proof.
In... Read more »
Editing human DNA has entered the public consciousness in a big way in recent years with its increasing use in laboratories—and, in recent news that shocked the scientific community, in embryos—of tools such as CRISPR-Cas9.
Locana, a gene therapy... Read more »
It’s been a year since Ford announced it will refurbish a massive abandoned train station in Detroit and transform it into the anchor of its mobility and autonomous vehicle operations, which will eventually house hundreds of employees.
This week, the automaker... Read more »
There’s a speed dating game of sorts happening as pharmaceutical companies that have approved cancer immunotherapies are testing their medications in combination with experimental drugs in hopes of reaching more patients.
Vice President for Research at UT Health Science Center at San Antonio
CEO of Foundry
Senior health advisor for Esri
Professor of Systems Biology, Columbia University
Director, Silicon Flatirons Centers' Entrepreneurship Initiative